Loading
Soquelitinib is an experimental small-molecule drug from Corvus Pharmaceuticals in phase 3 trials for peripheral T-cell lymphomas, with its target not yet stated publicly.
Soquelitinib (CPI-818) is a small-molecule drug developed by Corvus Pharmaceuticals. The sponsor describes its target as ITK (interleukin-2-inducible T-cell kinase), which OnCo does not yet have a target page for. The sponsor states: An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells. ClinicalTrials.gov describes the intervention as: Soquelitinib 200 mg tablets will be taken by mouth two times a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma), in peripheral T-cell lymphomas. The largest, NCT06561048, plans to enrol 150 participants with primary completion expected 2027-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells.
1.Soquelitinib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Soquelitinib" OR ABSTRACT:"Soquelitinib" OR TITLE:"CPI-818" OR ABSTRACT:"CPI-818") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Soquelitinib, not a curated reading list.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.